Skip to main content
. 2022 Aug 10;187(6):866–877. doi: 10.1111/bjd.21743

Figure 2.

Figure 2

Proportion of patients achieving clinical response and improvement in patient‐reported outcomes and health‐related quality‐of‐life during the induction period. (a) Static Physician’s Global Assessment (sPGA) score of 0 or 1. (b) ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90). (c) PASI 75. (d) PASI 100. (e) Involved body surface area (BSA) ≤ 1%. (f) Psoriasis Symptoms and Signs (PSS) symptoms free. (g) Dermatology Life Quality Index (DLQI) score of 0 or 1. Miri, mirikizumab; Pbo, placebo; Q4W, every 4 weeks. *P < 0·05 for mirikizumab vs. placebo using the Cochran–Mantel–Haenszel test stratified by prior biologics, weight and region.